Two receptors against three. Here is what that difference actually consists of, and why anyone thought adding a third was worth trying.
Receptor targets side by side
Tirzepatide binds the GIP receptor and the GLP-1 receptor. Both sit in the incretin system, which is how the gut signals to the pancreas that food has arrived.
Retatrutide binds those two and the glucagon receptor as well.
Why glucagon
Glucagon is usually described as insulin’s opposite number, raising blood sugar rather than lowering it, so adding it to this combination looks counterintuitive at first glance.
The interest is in energy expenditure. Glucagon receptor activity is associated with cells spending more energy, so the compound is pulling a different lever alongside the incretin ones rather than simply doing more of the same.
Structure
Both are synthetic peptides with fatty acid modifications that extend circulation time. Tirzepatide is built on the GIP sequence. Both are considerably larger molecules than most of this catalogue, which is why mass confirmation carries more weight on their certificates.
Development stage
Tirzepatide is licensed and has a substantial published literature behind it. Retatrutide is investigational, with a thinner literature weighted towards company-run trials, which is normal at this stage.
That difference matters when reading results. There is simply more independent work to draw on for one than the other.
Regulatory position in the UK
Tirzepatide is a licensed prescription-only medicine. Retatrutide is not licensed anywhere. Both are supplied here as laboratory reagents for in vitro research and neither is for human use.